Demographic and Prescribing Patterns of Chinese Herbal Products for Individualized Therapy for Ischemic Heart Disease in Taiwan: Population-Based Study

Hung, Yu Chiang; Tseng, Ying Jung; Hu, Wen Long; Chen, Hsuan Ju; Li, Tsai‐Chung; Tsai, Pei Yuan; Chen, Hsin Ping; Huang, Meng Hsuan; Su, Fang

doi:10.1371/journal.pone.0137058

Cited by 37 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 3 ] This increase is due to both the interest of patients in CAM for seeking help as well as exploration of the effectiveness of various therapies and interventions by researchers. [ 4 ]…”

Section: Introductionmentioning

confidence: 99%

The trends of utilization in traditional Chinese medicine in Taiwan from 2000 to 2010

Yeh

Chou²,

Huang

et al. 2016

Medicine

View full text Add to dashboard Cite

Introduction:There is no study exploring the trend of utilization in traditional Chinese medicine (TCM) from 2000 to 2010. The objective of this study was to investigate the trends of TCM utilization among 3 cross-sectional cohorts of 2000, 2005, and 2010.Method:This study was a cross-sectional analysis of TCM utilization over time. We compared the mean TCM visits among 3 cohorts of 2000, 2005, and 2010. We derived 3 randomly sampled cohorts of nearly 1 million representative beneficiaries in each of 2000, 2005, and 2010 from National Health Insurance Research Database for this research. Multivariate logistic regression was performed to evaluate the relative relationship in categorical variables correlating to TCM users. The percentage change (% change) in mean TCM visits between 2000 and 2005 (2010) was used to evaluate the trends of TCM utilization during the period.Results:The ratio of TCM users increased throughout cohorts. The ratio of TCM users among women was more than that among men in all cohorts of 2000, 2005, and 2010 (adjusted odds ratio = 1.47; 1.52; 1.62). The mean TCM visits increased from 2000 to 2010. The percentage change in mean TCM visits among women was more than that among men. The group aged less than 20 years had the least percentage change in mean TCM visits (18.8%); nevertheless, the group aged 20 to 34 years had the largest change (30.2%). The high socioeconomic status group had the largest percentage change in mean visits to TCM, whereas the central region had the least percentage change. Neoplasms had the greatest increase in percentage change in mean TCM visits among all disease categories; in contrast, diseases of the respiratory system had the greatest decrease.Conclusion:Both the ratio of TCM users and mean TCM visits increased gradually from 2000 to 2005 and further to 2010. Women used TCM more than men, and this is expected to continue in the future. The high socioeconomic status group used TCM more and more over time. The picture of TCM need among different types of cancer patients should be explored in further research because of the substantial increase in TCM utilization for the disease category of neoplasms.

show abstract

Section: Introductionmentioning

confidence: 99%

The trends of utilization in traditional Chinese medicine in Taiwan from 2000 to 2010

Yeh

Chou²,

Huang

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…According to this analysis and previous studies, [ 25 , 27 , 28 ] single and formula CHPs including Dan Shen, San Qi, Chuan Xiong, XFZYT, BYHWT, and ZGCT can be used to treat IHD and stroke. Dan Shen, a common CHP used to improve blood stasis in IHD patients, has antioxidant effects, inhibits smooth-muscle-cell proliferation, and protects against vascular atherosclerotic lesions by suppressing reactive oxygen species via the PKC/p44/42 MAPK-dependent pathway.…”

Section: Discussionmentioning

confidence: 81%

Decreased stroke risk with combined traditional Chinese and western medicine in patients with ischemic heart disease

Cheng

et al. 2020

Medicine

Self Cite

View full text Add to dashboard Cite

Both ischemic heart disease (IHD) and stroke are major causes of death worldwide. We investigated the effects of combined Traditional Chinese medicine (TCM) and western medicine (WM) on stroke risk in IHD patients. Taiwanese patients with IHD were enrolled in the TCM study during their outpatient visit. Stroke events after TCM or non-TCM treatment were examined. Chi-square tests and Student t -tests were used to examine differences between patients using and not using TCM. The Cox proportional hazards regression model was used to estimate hazard ratios (HRs). Sex, age, and comorbidities were included in a multivariable Cox model to estimate the adjusted HR (aHR). The survival probability and the probability free of stroke were calculated by the Kaplan–Meier method. There were 733 IHD patients using TCM and 733 using non-TCM treatment, with the same proportion of sex and age within each cohort. Using single Chinese herb such as Dan Shen, San Qi, or Chuan Xiong would have lower stroke events and lower aHR than non-TCM in IHD patients. There was 0.3-fold lower stroke risk in IHD patients with combination TCM and non-TCM treatment (95% CI = 0.11–0.84, P = .02). Moreover, the survival rate was higher ( P < .001) and the incidence of hemorrhagic stroke was significantly lower ( P = .04) in IHD patients with TCM treatment. IHD patients using combined TCM and WM had a higher survival rate and lower risk of new onset stroke, especially hemorrhagic stroke than those who did not use TCM treatment.

show abstract

“…Complex preparations containing ginsenosides have also been studied as cardioprotective agents, many of which are in common use for the treatment of coronary heart disease in Asian countries (Hung et al 2015). One of these herbal medications, Shenfu, is currently used in Asian societies, particularly China, as treatment for cardiovascular diseases as well as other conditions.…”

Section: Ginsenoside-containing Preparationsmentioning

confidence: 99%

Cardioprotection by ginseng: experimental and clinical evidence and underlying mechanisms

Gan

Karmazyn

2018

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

Protection of the ischemic and reperfused myocardium represents a major therapeutic challenge. Translating results from animal studies to the clinical setting has been disappointing, yet the need for effective intervention, particularly to limit heart damage following infarction or surgical procedures such as coronary artery bypass grafting, is substantial. Among the many compounds touted as cardioprotective agents is ginseng, a medicinal herb belonging to the genus Panax, which has been used as a medicinal agent for thousands of years, particularly in Asian societies. The biological actions of ginseng are very complex and reflect composition of many bioactive components, although many of the biological and therapeutic effects of ginseng have been attributed to the presence of steroid-like saponins termed ginsenosides. Both ginseng and many ginsenosides have been shown to exert cardioprotective properties in experimental models. There is also clinical evidence that traditional Chinese medications containing ginseng exert cardioprotective properties, although such clinical evidence is less robust primarily owing to the paucity of large-scale clinical trials. Here, we discuss the experimental and clinical evidence for ginseng, ginsenosides, and ginseng-containing formulations as cardioprotective agents against ischemic and reperfusion injury. We further discuss potential mechanisms, particularly as these relate to antioxidant properties.

show abstract

Demographic and Prescribing Patterns of Chinese Herbal Products for Individualized Therapy for Ischemic Heart Disease in Taiwan: Population-Based Study

Cited by 37 publications

References 28 publications

The trends of utilization in traditional Chinese medicine in Taiwan from 2000 to 2010

The trends of utilization in traditional Chinese medicine in Taiwan from 2000 to 2010

Decreased stroke risk with combined traditional Chinese and western medicine in patients with ischemic heart disease

Cardioprotection by ginseng: experimental and clinical evidence and underlying mechanisms

Contact Info

Product

Resources

About